ATE177841T1 - ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung - Google Patents

''crosstalk''- oder übersprech-inhibitoren und ihre verwendung

Info

Publication number
ATE177841T1
ATE177841T1 AT92910790T AT92910790T ATE177841T1 AT E177841 T1 ATE177841 T1 AT E177841T1 AT 92910790 T AT92910790 T AT 92910790T AT 92910790 T AT92910790 T AT 92910790T AT E177841 T1 ATE177841 T1 AT E177841T1
Authority
AT
Austria
Prior art keywords
ligand
crosstalk
binding
assay
analogue conjugate
Prior art date
Application number
AT92910790T
Other languages
English (en)
Inventor
Kenneth Francis Buechler
Richard Ray Anderson
Theodore Tsan-Tsung Lee
Gunars Edwin Valkirs
Original Assignee
Biosite Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosite Diagnostics Inc filed Critical Biosite Diagnostics Inc
Application granted granted Critical
Publication of ATE177841T1 publication Critical patent/ATE177841T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/822—Identified hapten

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Photolithography (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Stereophonic System (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Communication Cables (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92910790T 1991-04-10 1992-04-07 ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung ATE177841T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68345691A 1991-04-10 1991-04-10

Publications (1)

Publication Number Publication Date
ATE177841T1 true ATE177841T1 (de) 1999-04-15

Family

ID=24744132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92910790T ATE177841T1 (de) 1991-04-10 1992-04-07 ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung

Country Status (10)

Country Link
US (1) US5525524A (de)
EP (1) EP0585310B1 (de)
JP (1) JPH06506688A (de)
AT (1) ATE177841T1 (de)
AU (1) AU1772992A (de)
CA (1) CA2107894C (de)
DE (1) DE69228682T2 (de)
FI (1) FI934437L (de)
NO (1) NO933581L (de)
WO (1) WO1992018868A1 (de)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994103A (en) * 1995-06-02 1999-11-30 Human Genome Science, Inc. Human stanniocalcin-alpha
FR2751989B1 (fr) * 1996-08-01 1998-10-30 Soc D Rech Et De Dev En Activa Methode d'identification de cellules eucaryotes par fixation desdites cellules sur un support et support pour mettre en oeuvre ladite methode
US6544797B1 (en) * 1997-04-09 2003-04-08 Biosite Diagnostics, Inc. Compositions and methods for inhibiting light-induced inactivation of biological reagents
US6830731B1 (en) * 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6392894B1 (en) 1998-01-05 2002-05-21 Biosite Incorporated Media carrier for an assay device
US6096726A (en) * 1998-03-11 2000-08-01 Surface Solutions Laboratories Incorporated Multicomponent complex for use with substrate
EP1355666B1 (de) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von "repulsive guidance molecule" (rgm) und von dessen modulatoren
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US20040121350A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated System and method for identifying a panel of indicators
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040126767A1 (en) * 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
DE60233301D1 (de) * 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
EP1616181B1 (de) 2003-04-17 2009-08-12 Vermillion, Inc. Mit natriuretischen peptiden verwandte polypeptide und verfahren zu ihrer identifizierung und verwendung
EP1673465A4 (de) * 2003-09-29 2008-04-30 Biosite Inc Verfahren und zusammensetzungen zur sepsisdiagnose
AU2004298660B2 (en) 2003-12-12 2010-04-22 Abbott Rapid Diagnostics International Unlimited Company Assay
US6991911B2 (en) * 2003-12-15 2006-01-31 Dade Behring Inc. Assay for entactogens
US20050130243A1 (en) * 2003-12-15 2005-06-16 Zheng Yi F. Assay for entactogens
US7022492B2 (en) * 2003-12-15 2006-04-04 Dade Behring Inc. Ecstasy haptens and immunogens
US7115383B2 (en) * 2004-03-22 2006-10-03 Dade Behring Inc. Assays for amphetamine and methamphetamine
US7037669B2 (en) * 2004-03-22 2006-05-02 Dade Behring Inc. Assays for amphetamine and methamphetamine using stereospecific reagents
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
JP4581571B2 (ja) * 2004-09-06 2010-11-17 富士ゼロックス株式会社 粒子のマレイミジル基量を測定する定量方法
WO2006031583A2 (en) * 2004-09-09 2006-03-23 Biosite Incorporated Methods and compositions for measuring canine bnp and uses thereof
US20060084184A1 (en) * 2004-10-19 2006-04-20 Renovar Incorporated Reagents for urine-based immunological assays
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US7879979B2 (en) * 2005-01-21 2011-02-01 Alere International Arginine analogs, and methods for their synthesis and use
US20070269836A1 (en) * 2005-06-09 2007-11-22 Mcpherson Paul H Methods and compositions for the diagnosis of venous thromboembolic disease
US20070218498A1 (en) * 2005-08-30 2007-09-20 Buechler Kenneth F Use of soluble FLT-1 and its fragments in cardiovascular conditions
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
EP2005168A4 (de) * 2006-03-09 2009-05-20 Biosite Inc Verfahren und zusammensetzung zur diagnose von krankheiten der aorta
US20080118924A1 (en) * 2006-05-26 2008-05-22 Buechler Kenneth F Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
AU2007255981A1 (en) 2006-06-07 2007-12-13 Otago Innovation Limited Diagnostic methods and markers
CN101495868A (zh) * 2006-07-28 2009-07-29 博适公司 利用磁性颗粒进行受体结合试验的装置和方法
NZ576061A (en) 2006-09-07 2013-02-22 Otago Innovation Ltd Biomarkers
WO2008061149A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for diagnosis and prognosis of renal artery stenosis
WO2008060607A2 (en) 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US7903970B2 (en) * 2007-03-30 2011-03-08 Georgia Tech Research Corporation Optical network evaluation systems and methods
US7947465B2 (en) * 2007-08-20 2011-05-24 Bio-Rad Laboratories, Inc. Simultaneous assay for determining drugs
US20090053832A1 (en) * 2007-08-20 2009-02-26 Link William F Simultaneous assay for determining drugs
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5818440B2 (ja) * 2008-03-12 2015-11-18 オタゴ イノベーション リミテッド バイオマーカー
CA2715921A1 (en) 2008-03-12 2009-09-17 Otago Innovation Limited Biomarkers
BRPI0917711A2 (pt) 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
EP2324354B1 (de) 2008-08-29 2014-07-16 Astute Medical, Inc. Verfahren zur prognose von akuter niereninsuffizienz
CN104391115B (zh) 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ619918A (en) 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI0922021A2 (pt) 2008-11-10 2019-09-24 Astute Medical Inc método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
CN104034901A (zh) 2008-11-22 2014-09-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US20100204055A1 (en) * 2008-12-05 2010-08-12 Bonner-Ferraby Phoebe W Autoantibody detection systems and methods
US20120053072A1 (en) 2009-02-06 2012-03-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010210537B2 (en) 2009-02-06 2015-06-18 Astute Medical, Inc. Diagnosis and prognosis of renal injury and renal failure
US9752191B2 (en) 2009-07-09 2017-09-05 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
AU2010279302B2 (en) 2009-08-07 2015-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5827226B2 (ja) 2009-08-07 2015-12-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
EP3151005A1 (de) 2009-08-28 2017-04-05 Astute Medical, Inc. Verfahren zur diagnose von nierenläsion und niereninsuffizienz
NZ598741A (en) 2009-09-18 2013-07-26 Astute Medical Inc Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample
NZ630277A (en) 2009-09-21 2015-02-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2779905A1 (en) 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX340078B (es) 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
MX2012006560A (es) * 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
KR20120123056A (ko) 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
WO2011097540A1 (en) 2010-02-05 2011-08-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290627A1 (ru) 2010-02-05 2013-05-30 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EP2531620B1 (de) 2010-02-05 2016-12-14 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
EP2539712A4 (de) 2010-02-26 2013-09-18 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5786020B2 (ja) 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
EP2585827A4 (de) 2010-06-23 2013-12-04 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
MX2013000220A (es) 2010-06-23 2013-03-22 Astute Medical Inc Metodos y composiciones para diagnóstico y pronóstico de lesión renal e insuficiencia renal.
AU2011282245B2 (en) 2010-07-19 2017-09-28 Otago Innovation Limited Signal biomarkers
BR112013006631A2 (pt) 2010-09-24 2017-10-24 Astute Medical Inc métodos e composições para a avaliação de lesão renal utilizando ácido hialurônico
US10557856B2 (en) 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
EA201390293A1 (ru) 2010-10-07 2013-09-30 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
CN103370619B (zh) 2010-11-29 2016-01-20 美艾利尔圣地亚哥有限公司 诊断或风险预测心力衰竭的方法和试剂
EP3828544A1 (de) 2011-01-08 2021-06-02 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
US9551720B2 (en) 2011-01-26 2017-01-24 University of Pittsburgh—Of the Commonwaelth System of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
US20130330752A1 (en) 2011-01-29 2013-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103620407B (zh) * 2011-06-29 2016-09-21 美迪恩斯生命科技株式会社 非特异性反应抑制剂、非特异性反应抑制方法及试剂盒
TR201903235T4 (tr) 2011-08-26 2019-03-21 Astute Medical Inc Böbrek hasari ve böbrek yetmezli̇ği̇ni̇n tanilanmasi ve prognozuna yöneli̇k metotlar ve bi̇leşi̇mler.
AU2012340748A1 (en) 2011-11-22 2014-06-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2855570A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
JP6342812B2 (ja) 2011-12-14 2018-06-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
US20150050674A1 (en) 2012-02-27 2015-02-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2014011045A (es) 2012-03-13 2015-04-10 Abbvie Inc Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib.
US10114028B2 (en) 2012-03-20 2018-10-30 Upstream Medical Technologies Limited Biomarkers for pneumonia and acute decompensated heart failure
US20150293131A1 (en) 2012-04-02 2015-10-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
EP2841945A4 (de) 2012-04-24 2016-04-27 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von schlaganfall oder anderen hirnläsionen
EP3572809A1 (de) 2012-07-23 2019-11-27 Astute Medical, Inc. Verfahren zur diagnose von sepsis
EP2882767B1 (de) 2012-08-11 2023-07-12 Astute Medical, Inc. Bewertung von nierenläsionen mithilfe von hyaluronsäure
ES2681955T3 (es) 2013-01-17 2018-09-17 Astute Medical, Inc. Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
EP2970319A4 (de) 2013-03-14 2016-11-09 Alere San Diego Inc 6-acetylmorphin-analoga und verfahren zu deren synthese und verwendung
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US20160146832A1 (en) 2013-06-05 2016-05-26 Lakhmir S. Chawla Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
CA2920521A1 (en) 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
PH12016500358B1 (en) 2013-08-23 2023-08-16 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
WO2015031626A1 (en) 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015179773A1 (en) 2014-05-22 2015-11-26 The Scripps Research Institute Tissue molecular signatures of kidney transplant rejections
WO2015042465A1 (en) 2013-09-20 2015-03-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
EA201690731A1 (ru) 2013-11-06 2016-10-31 Астьют Медикал, Инк. Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2015103287A2 (en) 2013-12-30 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Genomic rearrangements associated with prostate cancer and methods of using the same
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3825416A3 (de) 2014-05-22 2021-09-15 The Scripps Research Institute Mit subklinischer nierentransplantatabstossung assoziierte genexpressionsprofile
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
AU2015263998A1 (en) 2014-05-22 2016-12-08 Northwestern University Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3968022A1 (de) 2014-10-20 2022-03-16 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
ES2943579T3 (es) 2014-12-18 2023-06-14 Astute Medical Inc Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3294416A4 (de) 2015-05-12 2018-11-21 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
WO2016201349A1 (en) 2015-06-11 2016-12-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3311164B1 (de) 2015-06-17 2022-04-20 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von appendizitis und differenzierung von ursachen für bauchschmerzen
JP2018523469A (ja) 2015-07-10 2018-08-23 ウエストバージニア ユニバーシティＷｅｓｔ Ｖｉｒｇｉｎｉａ Ｕｎｉｖｅｒｓｉｔｙ 脳卒中および脳卒中重篤度のマーカー
WO2017201314A1 (en) 2016-05-18 2017-11-23 Alere San Diego, Inc. 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018067468A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
US11633411B2 (en) 2016-10-04 2023-04-25 University Of Maryland, Baltimore Methods of treating sepsis using anti-sepsis lipid A (ASLA) based therapeutics
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
MX2019008260A (es) 2017-01-12 2020-01-27 Astute Medical Inc Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
EP3593134A1 (de) 2017-03-09 2020-01-15 Cleara Biotech B.V. Biomarker für zellalterung
CA3052513A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
ES3055047T3 (en) 2017-04-15 2026-02-09 Abbott Lab Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
CN110603449A (zh) 2017-04-28 2019-12-20 雅培实验室 用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
US20210025875A1 (en) 2017-05-07 2021-01-28 Astute Medical, Inc. Use of insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 in the management of renal replacement therapy
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
EP3649474A1 (de) 2017-07-03 2020-05-13 Abbott Laboratories Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
EP3721233A2 (de) 2017-12-09 2020-10-14 Abbott Laboratories Verfahren zur unterstützung bei der diagnose und bewertung eines patienten, der eine orthopädische verletzung erlitten hat und der eine verletzung des kopfes wie eine leichte traumatische hirnverletzung (tbi) hat oder möglicherweise erlitten hat, unter verwendung eines glialen fibrillären sauren proteins (gfap) und/oder einer ubiquitin-carboxy-terminalen hydrolase l1 (uch-l1)
EP3732196A4 (de) 2017-12-28 2022-01-05 Astute Medical, Inc. Antikörper und assays für ccl14
AU2018395255B2 (en) 2017-12-29 2025-02-20 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
EP3759213A4 (de) 2018-03-02 2022-03-16 Quantumcyte, Inc. Verfahren, zusammensetzungen und vorrichtungen zur isolierung und expressionsanalyse von interessierenden regionen aus einem gewebe
EP3788377A1 (de) 2018-05-04 2021-03-10 Abbott Laboratories Hbv-diagnostische, prognostische und therapeutische verfahren und produkte
EP3846797A4 (de) 2018-09-04 2022-06-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Verwendung von delta-tocotrienol zur behandlung von krebs
EP3903103B1 (de) 2018-12-28 2024-05-15 Abbott Laboratories Direkte detektion von einzelmolekülen auf mikropartikeln
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
US11079395B2 (en) 2019-03-01 2021-08-03 Abbott Laboratories Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
WO2020206385A1 (en) 2019-04-05 2020-10-08 Earli Inc. Improved methods and compositions for synthetic biomarkers
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
CN115803059A (zh) 2020-05-09 2023-03-14 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗covid-19的方法
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
EP4158352A1 (de) 2020-06-01 2023-04-05 Loop Diagnostics, S.L. Verfahren und kit zum frühen nachweis von sepsis
CA3188349A1 (en) 2020-08-04 2022-02-10 A. Scott Muerhoff Improved methods and kits for detecting sars-cov-2 protein in a sample
KR20230084469A (ko) 2020-08-04 2023-06-13 애보트 라피드 다이어그노스틱스 인터내셔널 언리미티드 컴퍼니 Sars-cov-2를 검출하기 위한 검정법
WO2022099216A1 (en) * 2020-11-09 2022-05-12 Children's Medical Center Corporation Systems and methods for high throughput screening of molecular interactions
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4259155A1 (de) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetische triterpenoide zur verwendung in der therapie
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4356129A1 (de) 2021-06-14 2024-04-24 Abbott Laboratories Verfahren zur diagnose oder unterstützung der diagnose von hirnverletzungen durch akustische energie, elektromagnetische energie, überdruckwelle und/oder explosionswind
WO2023028186A1 (en) 2021-08-27 2023-03-02 Abbott Laboratories Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
JP2024534849A (ja) 2021-08-31 2024-09-26 アボット・ラボラトリーズ 脳の損傷を診断する方法及びシステム
JP2024538608A (ja) 2021-09-30 2024-10-23 アボット・ラボラトリーズ 脳の損傷を診断する方法及びシステム
AU2022413677A1 (en) 2021-12-17 2024-06-27 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
EP4469565A1 (de) 2022-01-27 2024-12-04 Sanofi Pasteur Modifizierte vero-zellen und verfahren zur verwendung davon zur virusherstellung
EP4473311A1 (de) 2022-02-04 2024-12-11 Abbott Laboratories Lateralflussverfahren, tests und vorrichtungen zum nachweis oder zur messung der anwesenheit oder der menge von ubiquitincarboxyterminaler hydrolase l1 und/oder glialem fibrillärem saurem protein in einer probe
AU2023260822A1 (en) 2022-04-29 2024-11-14 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof
EP4514470A1 (de) 2022-04-29 2025-03-05 Broadwing Bio LLC Angiopoietin-verwandte protein-7-spezifische antikörper und verwendungen davon
AU2023260823A1 (en) 2022-04-29 2024-11-14 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
WO2024059692A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
KR20250068723A (ko) 2022-09-15 2025-05-16 아보트 러보러터리즈 경증 및 초경증 외상성 뇌 손상을 구분하기 위한 바이오마커 및 방법
EP4658687A1 (de) 2023-01-31 2025-12-10 University of Rochester Immuncheckpoint-blockadetherapie zur behandlung von staphylococcus-aureus-infektionen
WO2024211475A1 (en) 2023-04-04 2024-10-10 Abbott Laboratories Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024226969A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
US12122842B1 (en) 2023-09-27 2024-10-22 R&D Systems, Inc. Human CD30-specific binding proteins and uses thereof
WO2025111147A1 (en) 2023-11-21 2025-05-30 Abbott Laboratories Two-dimensional matrix droplet array
WO2026024666A1 (en) 2024-07-22 2026-01-29 Abbott Laboratories Systems and methods for digital detection assays
WO2026024677A1 (en) 2024-07-22 2026-01-29 Abbott Laboratories Method for determining the plasma volume of a blood sample and method for determining the dilution of plasma
WO2026024668A1 (en) 2024-07-22 2026-01-29 Abbott Laboratories Method of determining a volume of a liquid in a sample

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US4456716A (en) * 1982-12-29 1984-06-26 Ciba-Geigy Corporation 4-(Hydroxyphenylthio)imide stabilizers
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
US5068277A (en) * 1989-05-03 1991-11-26 Rhone-Poulenc Inc. Hydrolyzable silicone polymers

Also Published As

Publication number Publication date
FI934437A7 (fi) 1993-11-22
US5525524A (en) 1996-06-11
DE69228682D1 (de) 1999-04-22
FI934437L (fi) 1993-11-22
FI934437A0 (fi) 1993-10-08
EP0585310B1 (de) 1999-03-17
CA2107894A1 (en) 1992-10-11
CA2107894C (en) 2003-10-14
DE69228682T2 (de) 1999-07-01
AU1772992A (en) 1992-11-17
EP0585310A1 (de) 1994-03-09
NO933581D0 (no) 1993-10-07
WO1992018868A1 (en) 1992-10-29
NO933581L (no) 1993-12-10
JPH06506688A (ja) 1994-07-28
EP0585310A4 (de) 1995-06-14

Similar Documents

Publication Publication Date Title
ATE177841T1 (de) ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
DE3885220D1 (de) Toilette mit Vorrichtung zum Feststellen der Zusammensetzung von Urin.
AU7727491A (en) Improvements in or relating to methods for providing internal references for use in analyte-receptor assays
CA2145985A1 (en) Vascular endothelial cell growth factor antagonists
DE69412137D1 (de) Sensoreinrichtung zum sandwichtest
DK0770876T3 (da) En screening-fremgangsmåde til at identificere ligander for målproteiner
DE69418284D1 (de) Vorrichtung zur analyse von haptenen und ihre verwendung
GB2233463B (en) Method for determining the relative heat affected zone("haz")toughness of steel
NO964015L (no) Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer
ATE237353T1 (de) Antikörper gegen p-selectin und ihre verwendung
AU2002239882A1 (en) Method for identifying a ligand for a biological substrate
CA2207505A1 (en) Neurological drug screens
CA2271544A1 (en) Method to detect bone and other connective tissue disorders in humans and animals
DE69214843D1 (de) Verfahren zum nachweis von beschädigungen des magenepithels
DE3584949D1 (de) Vorrichtung zur mindestens naeherungsweisen bestimmung des querschnittes von langgestreckten gebilden.
PL322209A1 (en) Detection of antibody production
WO2000050455A3 (en) Antigen to systemic lupus erythematosis and diagnostic assay
FR2599513B1 (fr) Anticorps monoclonaux inhibant la liaison de ige soluble aux lymphocytes humains, hybridomes monoclonaux produisant de tels anticorps, leur utilisation
AU7190894A (en) Phosphate assay
DE69028023D1 (de) Verfahren zur Bestimmung des Cholesterins, zum Nachweis von Gefässkrankheiten und zur Anhebung des Anteils an HDL-Cholesterin
ATE148231T1 (de) Testsystem für degenerative muskelerkrankungen
DE69504991D1 (de) Verfahren zur bestimmung des lysingehaltes von samen
FI830311A7 (fi) määritysmenetelmä fysiologisesti aktiivisten haptenien pitoisuuden määrittämiseksi, jossa hapteeni sitoutuu immunogeenin kantajaan ja kilpailee haptenia vastaan olevien vasta-aineiden sitoutumispaikoista
ATE118617T1 (de) Enzym-quantifizierungstest auf einem docht.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties